Carl Zeiss Meditec Investors Back Dividend Amidst Sharp Profit Decline

Shareholders overwhelmingly approved the dividend, but Carl Zeiss Meditec faces a severe profit drop and a falling share price, with management withholding annual guidance.

A striking divergence was on display at Carl Zeiss Meditec's recent Annual General Meeting. Shareholders delivered near-unanimous support for the company's leadership and its proposed dividend, even as the medical technology group grapples with a severe contraction in profitability during its first fiscal quarter.

Shareholder Approval Meets Operational Headwinds

The voting results, released on Friday, demonstrate solid backing for the executive board. The distribution of a dividend of 0.55 euros per share, scheduled for payment on March 31, was approved with 99.99 percent of votes. This commitment to shareholder returns arrives during a period of significant operational strain.

For the first quarter of 2025/26, Carl Zeiss Meditec reported a 4.8 percent decline in revenue, which fell to 467.0 million euros. The drop in operating profit (EBITA) was far more severe, collapsing from 35.2 million euros to just 8.1 million euros. Consequently, earnings per share turned negative, landing at -0.06 euros.

This fundamental weakness is mirrored in the stock's performance. Closing at 24.18 euros on Friday, the share price has declined by nearly 39 percent since the start of the year. This places the equity dangerously close to its 52-week low of 23.38 euros, a level recorded just days prior.

Management Cites External Pressures, Withholds Annual Guidance

Company executives attribute the profit weakness to negative currency translation effects and noticeable investment hesitation in its core U.S. market. In response, the firm is accelerating cost-reduction initiatives and pushing for greater product localization within Asia. A first move in this strategic shift came in February, with Chinese regulatory approval for a new bifocal intraocular lens.

The management team has refrained from providing reliable guidance for the full fiscal year. This caution aligns with the current skepticism among market analysts, whose recent assessments include:
* Barclays: Price target of 30.00 euros (Rating: "Equal Weight")
* JPMorgan: Price target of 22.40 euros (Rating: "Underweight")

In the absence of a clear fundamental catalyst, investor focus now shifts to the interim results scheduled for release on May 12. This date represents a critical deadline for management to demonstrate whether its newly launched restructuring measures can halt the margin erosion in the second half and effectively quantify the impact of national procurement tenders in China into a credible full-year forecast.